quinta-feira, dezembro 23, 2004

FDA aprova nova formulação do Invirase

Reuters Health 20.12.04

The U.S. Food and Drug Administration (FDA) has granted approval to a more potent formulation of Roche AG's HIV drug Invirase (saquinavir), meaning that patients will not need to take as many of the pills.

The FDA approved the drug in a 500-mg formulation, cutting the daily pill requirement from 5 to 2, Roche said in a statement on Monday.

Invirase, which is not among the Swiss drugmaker's top 20 products, was launched in 1995 and was the first HIV protease inhibitor on the market.

Comments: Enviar um comentário

<< Home

This page is powered by Blogger. Isn't yours?

Enter your email address below to subscribe to Blog do GAT!

powered by Bloglet